Thursday, November 21, 2024
11/21/2024
PROJECT SUMMARY Asthma affects 5% of the world population. In the U.S., asthma death rates are four-fold higher in Latinos and African Americans compared to Whites. Childhood asthma is a complex disease historically defined by partially overlapping clinical features. However, the heterogeneity observed in clinical disease and airway pathology suggests that the standard definition of asthma is composed of multiple clinical subgroups each with a distinct pathogenesis (i.e. endotypes). Gene expression profiling of bronchial airway brushings identified the type 2- high asthma endotype, defined by excessive airway inflammation driven by type 2 cytokines. We found that the type 2-high asthma endotype can be identified by gene expression profiling of minimally invasive nasal airway epithelium brushings. We also found high nasal expression of the type 2 cytokine, IL-13, was associated with higher risk of asthma attacks among Puerto Ricans, who have the highest asthma morbidity and mortality in the U.S. The populations with the highest asthma morbidity also have the poorest response to the most common asthma medication, albuterol. We hypothesize that specific molecular airway endotypes will define children with severe asthma and poor drug response and that these endotypes will have a strong genetic basis. To investigate this hypothesis the following aims are proposed: (1) Determine the expression endotypes of childhood asthma that underlie poor albuterol drug response and severe disease, using minimally invasive samples. Molecular endotyping with be performed by computational analysis of whole transcriptome sequencing data generated from 745 asthmatic and healthy children. Correlates of airway endotypes will be identified using peripheral blood gene expression. (2) Determine how IL-13 modifies airway cell responses to albuterol and HRV infection, and the genetic control of these responses. A powerful in vitro airway epithelial model will be used to determine if type 2 inflammation of the airway epithelium modifies transcriptional response to albuterol (most common asthma medication) and human rhinovirus (HRV) infection (most common trigger of asthma attacks). (3) Determine the genetic basis of and validate poor drug response and severe asthma endotypes in ethnically diverse children. We will perform the first genetic screen of type 2-high and other asthma endotypes. We will examine data from 4,379 minority children with asthma to determine how asthma endotypes influence response to albuterol and risk for severe asthma. Our goal is to understand the genetic basis of racial/ethnic differences in asthma severity and lung function. Results from this proposal will inform public health policy and clinical practice and aide in the mechanistic understanding of asthma severity (morbidity), which may lead to more targeted therapies. Data generated from our proposal will become a valuable resource for the medical and scientific communities.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
